Exact Mass: 409.0748612

Exact Mass Matches: 409.0748612

Found 19 metabolites which its exact mass value is equals to given mass value 409.0748612, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

Lifibrate

1-Methylpiperidin-4-yl 2,2-bis(4-chlorophenoxy)acetic acid

C20H21Cl2NO4 (409.08475660000005)


C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C98150 - Fibrate Antilipidemic Agent

   

methionine aspartate aspartate

4,11-diamino-3,6,9,12-tetraoxo-1,2,7,8-tetraoxacyclododecan-4-yl 2-amino-4-(methylsulfanyl)butanoate

C13H19N3O10S (409.0791114)


   
   

cladoniamide D

cladoniamide D

C21H16ClN3O4 (409.08292860000006)


An organic heteropentacyclic compound that is cladoniamide E in which the chlorine attached to the methoxy-bearing indole moiety is replaced by a hydrogen. It has been isolated from the culture broth of Streptomyces uncialis.

   
   

cladoniamide F

cladoniamide F

C21H16ClN3O4 (409.08292860000006)


An organic heteropentacyclic compound that is cladoniamide G in which the chlorine attached to the methoxy-bearing indole moiety is replaced by a hydrogen. It has been isolated from the culture broth of Streptomyces uncialis.

   
   

2-CHLORO-5-(TRIBUTYLSTANNYL)-1,3-THIAZOLE

2-CHLORO-5-(TRIBUTYLSTANNYL)-1,3-THIAZOLE

C15H28ClNSSn (409.0652868)


   

Fanapanel

Fanapanel

C14H15F3N3O6P (409.06505360000006)


C26170 - Protective Agent > C1509 - Neuroprotective Agent Fanapanel (ZK200775) is a highly selective AMPA/kainate antagonist with little activity against NMDA; have Ki values of 3.2 nM, 100 nM, and 8.5 μM against quisqualate, kainate, and NMDA, respectively.

   

3-[5-[(4-Chlorophenyl)methylthio]-1,3,4-oxadiazol-2-yl]-1-(phenylmethyl)-2-pyridinone

3-[5-[(4-Chlorophenyl)methylthio]-1,3,4-oxadiazol-2-yl]-1-(phenylmethyl)-2-pyridinone

C21H16ClN3O2S (409.06517060000004)


   

3-[(4-Bromophenyl)amino]-3-(4-methoxyphenyl)-1-phenylpropan-1-one

3-[(4-Bromophenyl)amino]-3-(4-methoxyphenyl)-1-phenylpropan-1-one

C22H20BrNO2 (409.06773200000003)


   

lifibrate

lifibrate

C20H21Cl2NO4 (409.08475660000005)


C78276 - Agent Affecting Digestive System or Metabolism > C29703 - Antilipidemic Agent > C98150 - Fibrate Antilipidemic Agent

   

(E)-3-(1,3-benzothiazol-2-yl)-4-(5-chloro-3-methyl-1-phenylpyrazol-4-yl)but-3-enoic acid

(E)-3-(1,3-benzothiazol-2-yl)-4-(5-chloro-3-methyl-1-phenylpyrazol-4-yl)but-3-enoic acid

C21H16ClN3O2S (409.06517060000004)


   

N-(1,3-benzodioxol-5-yl)-2-[(8-methoxy-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio]acetamide

N-(1,3-benzodioxol-5-yl)-2-[(8-methoxy-5H-[1,2,4]triazino[5,6-b]indol-3-yl)thio]acetamide

C19H15N5O4S (409.08447100000006)


   

MMRi64

MMRi64

C22H17Cl2N3O (409.0748612)


MMRi64 disrupts Mdm2-MdmX interactions. MMRi64 downregulates Mdm2 and MdmX in leukemia cells. MMRi64 induces p53 accumulation, and induces the apoptotic arm of the p53 pathway in leukemia/lymphoma cells. MMRi64 can be used for cancer research[1].

   

n-{3-[(4s)-1-[(1e)-2-(3-bromo-4-methoxyphenyl)ethenyl]-2-hydroxy-5-oxo-4h-imidazol-4-yl]propyl}guanidine

n-{3-[(4s)-1-[(1e)-2-(3-bromo-4-methoxyphenyl)ethenyl]-2-hydroxy-5-oxo-4h-imidazol-4-yl]propyl}guanidine

C16H20BrN5O3 (409.0749430000001)